Business context and reporting period
The supplied filing is Trovagene, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015—not a Cardiff Oncology filing. The company develops and commercializes urine- and blood-based cell-free DNA molecular diagnostics, with a primary focus on cancer monitoring. Its tests and commercialization efforts were at an early stage.
Financial performance and liquidity
- Revenue: Second-quarter revenue was $49,346, down from $55,628 a year earlier. Six-month revenue was $176,316, up from $166,581. Revenue was principally royalties; diagnostic-service revenue was only $2,520 for the quarter and $4,686 for the six months.
- Losses and expenses: Second-quarter net loss attributable to common stockholders was $10.19 million ($0.41 per share), versus $1.08 million ($0.06) in 2014. Six-month net loss was $17.37 million ($0.75 per share), versus $4.28 million ($0.23). Six-month operating expenses rose to $11.66 million from $6.67 million.
- Margins: Diagnostic-service cost of revenue was $80,030 for the quarter and $256,455 for the six months, exceeding the corresponding service revenue in both periods. Management cited low test volume and capacity inefficiencies; costs may be recorded before related cash-basis revenue.
- Cash flow: Six-month operating cash use was $10.18 million, compared with $5.45 million in 2014; capital expenditures were $688,000. Financing provided $24.87 million, primarily from equity issuance.
- Cash and liquidity: Cash and equivalents were $41.29 million at June 30, 2015, and working capital was $36.95 million. After quarter-end, the company received approximately $37.4 million net from a July public offering; it reported July 31 working capital of $73.01 million.
- Debt: Long-term loan principal was $15.0 million, with a 7.07% interest rate and maturity in July 2018. An equity-proceeds condition was amended and met, extending interest-only payments to February 1, 2016; principal and interest payments then commence. The loan is secured by company assets other than intellectual property, which is subject to a negative pledge.
Material changes, outlook and risks
- Losses increased substantially as research and development, selling and marketing, and general and administrative expenses rose. Management attributed growth mainly to expanded clinical collaborations, staffing, laboratory activity, and marketing. It expected these expenses and operating cash outflows to continue increasing or persist for the next several years.
- A $5.12 million six-month non-cash loss from revaluing warrant derivative liabilities materially increased reported losses; the liability rose to $7.69 million from $3.01 million at year-end, largely reflecting the higher share price and valuation inputs.
- The company reported more than 25 active collaborations or studies and cited clinical results as supportive of its platform, but emphasized that development and commercialization remained early-stage and that future revenue timing and amounts were uncertain. No specific financial guidance was provided.
- Management identified substantial risks, including inability to achieve profitability, clinical and regulatory uncertainty, competition, reimbursement and market-acceptance challenges, need for additional capital and potential dilution. Diagnostic-service revenue recognition was based on cash collection while reimbursement estimates remained difficult to make.
- Other notable items: the company expanded its lease commitment to approximately 22,600 square feet at about $60,000 monthly rent once it occupies the expanded premises, with the lease ending December 31, 2021. It reported no material pending legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of June 30, 2015.
Most important facts for investors to verify
- Confirm the issuer: the provided filing identifies Trovagene, Inc., whereas the request metadata names Cardiff Oncology, Inc.
- Review the July 2015 offering proceeds, post-offering share count, and dilution; the filing reports 29,622,602 common shares outstanding as of July 31 and 11.66 million potentially dilutive securities excluded from diluted EPS at June 30.
- Assess cash consumption against the company’s continued operating losses and the timing of scheduled principal payments beginning February 2016.
- Track test volumes, reimbursement collections, and whether diagnostic-service economics improve from the reported negative service gross margin.
- Evaluate clinical evidence, regulatory requirements, reimbursement coverage, and the ability to convert collaborations and marketing activity into recurring revenue.